NCT05699993View on ClinicalTrials.gov

A Study of IBI351 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

October 16, 2023

Study Completion Date

October 16, 2023

Conditions
Healthy Subjects
Interventions
DRUG

Itraconazole

Itraconazole was administered orally

DRUG

IBI351

IBI351 was administered orally

DRUG

Dextromethorphan

Dextromethorphan was administered orally

Trial Locations (1)

Unknown

The First Affiliated Hospital of Suzhou University, Suzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY